PERSON
Ascendis Hormone Replacement Therapy Faces Setback with FDA Review Extension
Ascendis Pharma, hormone replacement therapy, FDA review, delay, three-month extension.
Revolutionizing Protein Design: Nabla Bio Secures $26M for AI-Driven Pharmaceutical Solutions
Nabla Bio, genAI protein design, funding, pharmaceutical partners, biotechnology, protein engineering, drug discovery, artificial intelligence, healthcare innovation.
Extended FDA Review Timeline for Ascendis’ Hormone Therapy
Ascendis Pharma, hormone therapy, FDA review, delay, 3 months extension.
FDA Imposes Three-Month Delay on Ascendis’ Hypoparathyroidism Treatment
Ascendis Pharma, hypoparathyroidism, FDA, drug approval, delay, three-month setback, regulatory hurdle, treatment, endocrine disorder.
Revolutionizing Pharmaceuticals: Nabla Bio Secures $26M for AI-Powered Protein Design
Nabla Bio, generative AI, protein design, funding, pharmaceutical partners, biotechnology, drug discovery.
Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS
Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.
Revolutionizing Cardiac Mapping: J&J’s Biosense Webster Integrates AI into Carto 3 System
J&J, Biosense Webster, AI, Carto 3 system, cardiac mapping, heart mapping, electrophysiology, medical technology, healthcare innovation.
Sanofi’s Chief Scientific Officer Frank Nestle Announces Departure
Sanofi, Frank Nestle, Chief Scientific Officer, resignation, pharmaceutical industry, leadership change.
Revolutionizing Public Health: CBER’s Peter Marks and the Vision to Reduce FDA Visits
CBER, Peter Marks, FDA, public health, healthcare innovation, regulatory affairs, biologics, vaccines, medical devices, preventive measures.
Chiesi Invests Heavily in Gossamer’s Promising Pulmonary Hypertension Treatment
Chiesi, Gossamer, pulmonary hypertension, drug development, investment, collaboration, GD-001, clinical trials, cardiovascular diseases.